MA40523B1 - 2-(morpholin-4-yl)-1,7-naphthyridines - Google Patents

2-(morpholin-4-yl)-1,7-naphthyridines

Info

Publication number
MA40523B1
MA40523B1 MA40523A MA40523A MA40523B1 MA 40523 B1 MA40523 B1 MA 40523B1 MA 40523 A MA40523 A MA 40523A MA 40523 A MA40523 A MA 40523A MA 40523 B1 MA40523 B1 MA 40523B1
Authority
MA
Morocco
Prior art keywords
compounds
morpholin
preparation
naphthyridines
disease
Prior art date
Application number
MA40523A
Other languages
English (en)
Other versions
MA40523A (fr
Inventor
Gerhard Siemeister
Antje Margret Wengner
Hans Briem
Knut Eis
Philip Lienau
Wilhelm Bone
Lars Wortmann
Ulrich Lücking
Marcus Koppitz
Benjamin Bader
Julien Lefranc
Joanna Grudzinska-Goebel
Dieter Moosmayer
Uwe Eberspächer
Hans Schick
Nussbaum Franz Von
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA40523A publication Critical patent/MA40523A/fr
Publication of MA40523B1 publication Critical patent/MA40523B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur des composés 2-(morpholin-4-yl)-l,7-naphtyridine substitués représentés par la formule générale (i) ou (ib), sur des procédés de préparation desdits composés, sur des composés intermédiaires utiles pour la préparation desdits composés, sur des combinaisons et des compositions pharmaceutiques comprenant lesdits composés et sur l'utilisation desdits composés pour la fabrication d'une composition pharmaceutique utile pour le traitement ou la prophylaxie d'une maladie, en particulier d'une maladie hyperproliférative en tant qu'agent unique ou en combinaison avec d'autres principes actifs.
MA40523A 2014-08-04 2015-08-03 2-(morpholin-4-yl)-1,7-naphthyridines MA40523B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14179692 2014-08-04
EP15159342 2015-03-17
EP15744596.6A EP3177619B1 (fr) 2014-08-04 2015-08-03 2-(morpholin-4-yl)-1,7-naphthyridines
PCT/EP2015/067804 WO2016020320A1 (fr) 2014-08-04 2015-08-03 2- (morpholin -4-yl)-l,7-naphtyridines

Publications (2)

Publication Number Publication Date
MA40523A MA40523A (fr) 2017-06-14
MA40523B1 true MA40523B1 (fr) 2018-09-28

Family

ID=53762196

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40523A MA40523B1 (fr) 2014-08-04 2015-08-03 2-(morpholin-4-yl)-1,7-naphthyridines

Country Status (42)

Country Link
US (4) US9993484B2 (fr)
EP (2) EP3177619B1 (fr)
JP (2) JP6266839B2 (fr)
KR (2) KR102180006B1 (fr)
CN (3) CN110204544B (fr)
AP (1) AP2017009702A0 (fr)
AU (2) AU2015299173B2 (fr)
BR (1) BR112017002221B1 (fr)
CA (1) CA2956992A1 (fr)
CL (1) CL2017000287A1 (fr)
CO (1) CO2017001035A2 (fr)
CR (1) CR20170034A (fr)
CU (1) CU24419B1 (fr)
CY (2) CY1120673T1 (fr)
DK (2) DK3177619T3 (fr)
DO (1) DOP2017000038A (fr)
EA (2) EA035039B1 (fr)
EC (1) ECSP17007538A (fr)
ES (2) ES2900599T3 (fr)
HR (2) HRP20211770T1 (fr)
HU (2) HUE038533T2 (fr)
IL (2) IL250220B (fr)
JO (1) JO3447B1 (fr)
LT (2) LT3177619T (fr)
MA (1) MA40523B1 (fr)
MX (2) MX2020010333A (fr)
MY (1) MY192883A (fr)
NI (1) NI201700011A (fr)
PE (1) PE20170666A1 (fr)
PH (2) PH12017500204A1 (fr)
PL (2) PL3177619T3 (fr)
PT (1) PT3177619T (fr)
RS (2) RS57445B1 (fr)
SA (1) SA517380830B1 (fr)
SG (1) SG11201700750UA (fr)
SI (2) SI3177619T1 (fr)
TN (1) TN2017000027A1 (fr)
TW (2) TWI700283B (fr)
UA (2) UA121036C2 (fr)
UY (1) UY36254A (fr)
WO (1) WO2016020320A1 (fr)
ZA (1) ZA202101003B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI700283B (zh) * 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
KR102538658B1 (ko) 2014-08-04 2023-05-31 누에볼루션 에이/에스 염증성, 대사성, 종양성 및 자가면역성 질환의 치료에 유용한 피리미딘의 임의적 융합 헤테로시클릴-치환 유도체
JP6873145B2 (ja) * 2016-01-14 2021-05-19 バイエル・ファルマ・アクティエンゲゼルシャフト ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018153972A1 (fr) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de kinase atr et d'anti-androgènes
JOP20190197A1 (ar) * 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
EP3585365B1 (fr) 2017-02-24 2021-08-25 Bayer Pharma Aktiengesellschaft Combinaison de atr kinase inhibiteurs avec parp inhibiteurs
WO2018153975A1 (fr) 2017-02-24 2018-08-30 Bayer As Polythérapie comprenant un agent radiopharmaceutique et un inhibiteur de réparation d'adn
WO2018153971A1 (fr) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de kinase atr
AR110995A1 (es) 2017-02-24 2019-05-22 Bayer Ag Combinación de inhibidores de quinasa atr con sal de radio-223
WO2018153970A1 (fr) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Formes solides de 2-[(3r)-3-méthylmorpholin-4-yl]-4-(1-méthyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphtyridine
WO2018206547A1 (fr) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de bub1 et d'atr
WO2018218197A2 (fr) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Inhibiteurs de la kinase atr à base de tétrahydropyrido[4,3-d]pyrimidine
FI3651768T3 (fi) 2017-07-13 2024-03-14 Univ Texas Heterosyklisiä ATR-kinaasin inhibiittoreita
JOP20200024A1 (ar) * 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
WO2019025440A1 (fr) 2017-08-04 2019-02-07 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de kinase atr et d'inhibiteurs de pd-1/pd-l1
EP3661917B1 (fr) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft Dérivés 6-((3-trifluorométhyl)phényl)-4,5-dihydropyridazin-3(2h)-one en tant qu'inhibiteurs de pde3a et pde3b pour le traitement du cancer
JP7290627B2 (ja) 2017-08-17 2023-06-13 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
WO2019057852A1 (fr) 2017-09-22 2019-03-28 Bayer Aktiengesellschaft Utilisation de kap1 en tant que biomarqueur pour la détection ou la surveillance de l'inhibition d'atr chez un sujet
EP3461480A1 (fr) 2017-09-27 2019-04-03 Onxeo Combinaison d'inhibiteurs de point de contrôle du cycle cellulaire de réponse à un dommage à l'adn et de belinostat pour traiter le cancer
EP3720973A1 (fr) * 2017-12-08 2020-10-14 Bayer Aktiengesellschaft Marqueurs prédictifs pour inhibiteurs d'atr kinase
IL276489B1 (en) * 2018-02-07 2024-05-01 Shijiazhuang Sagacity New Drug Dev Company Ltd ATR inhibitor and its application
US10894052B2 (en) 2018-03-16 2021-01-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
ES2950825T3 (es) * 2018-08-24 2023-10-13 Bayer Ag Procedimiento para preparar 2-[(3R)-3--metilmofolin--4-il]-4-(1-metil-1H-pirazol-5-il)-8-(1H-pirazol-5-il)-1,7-naftiridina
WO2020078788A1 (fr) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combinaison d'inhibiteurs de kinase atr avec des composés de 2,3-dihydro-imidazo[1,2-c]quinazoline
SG11202104460UA (en) * 2018-10-30 2021-05-28 Repare Therapeutics Inc Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
MX2021009550A (es) 2019-02-11 2021-09-08 Bayer Ag Inhibidor de la quinasa atr para usar en el tratamiento de una enfermedad hiperproliferativa.
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
AU2020317381A1 (en) * 2019-07-22 2022-02-10 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
TW202128690A (zh) * 2019-11-21 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 吡唑并雜芳基類衍生物、其製備方法及其在醫藥上的應用
KR20220128350A (ko) * 2019-12-11 2022-09-20 리페어 세라퓨틱스 인크. Parp 억제제와 조합되는 atr 억제제의 용도
EP4076657A1 (fr) 2019-12-20 2022-10-26 Nuevolution A/S Composés actifs vis-à-vis des récepteurs nucléaires
EP4126874A1 (fr) 2020-03-31 2023-02-08 Nuevolution A/S Composés actifs vis-à-vis des récepteurs nucléaires
MX2022012259A (es) 2020-03-31 2022-12-08 Nuevolution As Compuestos activos frente a receptores nucleares.
CA3185491A1 (fr) * 2020-07-03 2022-01-06 Antengene Discovery Limited Inhibiteurs d'atr et leurs utilisations
CA3185963A1 (en) * 2020-07-13 2022-01-20 Cheung Ling Cheng Pyrazolopyrimidine compound used as atr kinase inhibitor
CN112110934B (zh) * 2020-09-23 2021-12-07 上海应用技术大学 一种基于azd9291的生物标记物及其制备方法与应用
CN116234551A (zh) * 2020-09-27 2023-06-06 南京明德新药研发有限公司 一类1,7-萘啶类化合物及其应用
US20240059695A1 (en) * 2020-12-25 2024-02-22 Impact Therapeutics (Shanghai), Inc SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND USE THEREOF
CN117355524A (zh) * 2021-05-21 2024-01-05 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的可药用盐及其结晶形式
CN115677730A (zh) * 2021-07-27 2023-02-03 上海辉启生物医药科技有限公司 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
AU2022325376A1 (en) * 2021-08-11 2024-02-22 Wigen Biomedicine Technology (shanghai) Co., Ltd. Naphthyridine derivative as atr inhibitor and method for preparing same
CN116731011A (zh) * 2022-03-01 2023-09-12 武汉众诚康健生物医药科技有限公司 一种萘啶衍生物及其应用
WO2023242302A1 (fr) 2022-06-15 2023-12-21 Astrazeneca Ab Polythérapie pour le traitement du cancer

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1307271A (en) 1970-06-25 1973-02-14 Shell Int Research Sulphoximine derivatives and their use in herbicidal compositions
US4008068A (en) * 1976-03-08 1977-02-15 Velsicol Chemical Corporation 1-Thiadiazolyl-5-morpholinoimidazolidinones
WO2000058307A2 (fr) 1999-03-11 2000-10-05 Neurogen Corporation Pyridines 2,4-disubstituees fusionnees avec un aryle: ligands du recepteur nk-3
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2007000445A1 (fr) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Derives de benzyle-benzene a substitution glucopyranosyle, medicaments contenant de tels composes, utilisation et production de ces derniers
JP5161102B2 (ja) * 2005-11-22 2013-03-13 クドス ファーマシューティカルズ リミテッド ｍＴＯＲ阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体
DE102005062742A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
EP1803723A1 (fr) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft Dérivés (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximide en tant qu'inhibiteurs de la kinase aurora pour le traitement de cancer
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
ES2301380B1 (es) * 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
DK2057156T3 (en) * 2006-08-23 2017-05-08 Kudos Pharm Ltd 2-METHYLMORPHOLINPYRIDO, PYRAZO AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS
EP2342190A1 (fr) * 2008-09-02 2011-07-13 Novartis AG Inhibiteurs bicycliques des kinases
WO2010037765A2 (fr) * 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
CA2743134A1 (fr) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Composes utiles comme inhibiteurs de l'atr kinase
US20100144345A1 (en) 2008-12-09 2010-06-10 Microsoft Corporation Using called party mobile presence and movement in communication application
EP3354650B1 (fr) 2008-12-19 2022-02-16 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de kinase d'atr
UY32351A (es) * 2008-12-22 2010-07-30 Astrazeneca Ab Compuestos de pirimidinil indol para uso como inhibidores de atr
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2569287B1 (fr) 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Composés utilisables en tant qu'inhibiteurs de la kinase atr
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な化合物
EP2569284B1 (fr) 2010-05-12 2015-07-08 Vertex Pharmaceuticals Incorporated Dérivés de 2-aminopyridine utiles en tant qu'inhibiteurs de la kinase atr
WO2011143423A2 (fr) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Composés utilisables en tant qu'inhibiteurs de la kinase atr
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
MX2013000103A (es) * 2010-06-23 2013-06-13 Vertex Pharma Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
CA2803358A1 (fr) * 2010-06-30 2012-01-05 Amgen Inc. Composes heterocycliques et leur emploi en tant qu'inhibiteurs de l'activite de pi3k
MX2013011450A (es) 2011-04-05 2014-02-03 Vertex Pharma Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2012178123A1 (fr) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de la kinase atr
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US8846656B2 (en) * 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CA2850564A1 (fr) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Composes utiles comme inhibiteurs de kinase atr
RU2018108589A (ru) 2011-09-30 2019-02-25 Вертекс Фармасьютикалз Инкорпорейтед Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776420A1 (fr) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Composés de pyrazine utiles comme inhibiteurs de kinase atr
EP2776421A1 (fr) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de kinase atr
EP2776422A1 (fr) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de la kinase atr
EP2776429A1 (fr) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de kinase atr
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SI2833973T1 (en) 2012-04-05 2018-04-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase and their combination therapy
WO2014062604A1 (fr) 2012-10-16 2014-04-24 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de la kinase atr
BR112015012454B1 (pt) 2012-12-07 2022-07-05 Vertex Pharmaceuticals Incorporated Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos
EP2944637B1 (fr) 2013-01-11 2020-02-19 FUJIFILM Corporation Composé hétérocyclique contenant de l'azote ou sel de celui-ci
EP2970286A1 (fr) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Dérivés de pyrazolopyrimidine fusionnés utiles en tant qu'inhibiteurs de la kinase atr
TWI700283B (zh) * 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
JP6873145B2 (ja) * 2016-01-14 2021-05-19 バイエル・ファルマ・アクティエンゲゼルシャフト ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン
WO2018153975A1 (fr) 2017-02-24 2018-08-30 Bayer As Polythérapie comprenant un agent radiopharmaceutique et un inhibiteur de réparation d'adn
EP3585365B1 (fr) 2017-02-24 2021-08-25 Bayer Pharma Aktiengesellschaft Combinaison de atr kinase inhibiteurs avec parp inhibiteurs
AR110995A1 (es) 2017-02-24 2019-05-22 Bayer Ag Combinación de inhibidores de quinasa atr con sal de radio-223
JOP20190197A1 (ar) 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
WO2018153970A1 (fr) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Formes solides de 2-[(3r)-3-méthylmorpholin-4-yl]-4-(1-méthyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphtyridine
WO2018153971A1 (fr) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de kinase atr
WO2018153972A1 (fr) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de kinase atr et d'anti-androgènes
WO2018206547A1 (fr) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de bub1 et d'atr
PL3646094T3 (pl) 2017-06-28 2022-11-28 Corning Research & Development Corporation Wieloporty mające porty połączeniowe z elementami mocującymi
WO2019025440A1 (fr) 2017-08-04 2019-02-07 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de kinase atr et d'inhibiteurs de pd-1/pd-l1
EP3720973A1 (fr) 2017-12-08 2020-10-14 Bayer Aktiengesellschaft Marqueurs prédictifs pour inhibiteurs d'atr kinase
ES2950825T3 (es) 2018-08-24 2023-10-13 Bayer Ag Procedimiento para preparar 2-[(3R)-3--metilmofolin--4-il]-4-(1-metil-1H-pirazol-5-il)-8-(1H-pirazol-5-il)-1,7-naftiridina
JP2022504333A (ja) 2018-10-05 2022-01-13 アイエスピー インヴェストメンツ エルエルシー 水溶性セルロースエーテルを含有する平滑な高固形分フィルムコーティング組成物、その調製方法およびその使用方法
WO2020078788A1 (fr) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combinaison d'inhibiteurs de kinase atr avec des composés de 2,3-dihydro-imidazo[1,2-c]quinazoline
MX2021009550A (es) 2019-02-11 2021-09-08 Bayer Ag Inhibidor de la quinasa atr para usar en el tratamiento de una enfermedad hiperproliferativa.

Also Published As

Publication number Publication date
KR102317169B1 (ko) 2021-10-27
EP3395818A1 (fr) 2018-10-31
JP6266839B2 (ja) 2018-01-24
US20170216304A1 (en) 2017-08-03
LT3395818T (lt) 2021-11-25
CN106795156A (zh) 2017-05-31
MX2020010333A (es) 2022-08-03
PH12021550792A1 (en) 2021-12-13
RS62609B1 (sr) 2021-12-31
US10772893B2 (en) 2020-09-15
ES2679625T3 (es) 2018-08-29
SI3395818T1 (sl) 2022-01-31
WO2016020320A8 (fr) 2017-04-06
US11529356B2 (en) 2022-12-20
AU2019204125A1 (en) 2019-07-04
EA201790306A1 (ru) 2017-08-31
IL268969A (en) 2019-10-31
RS57445B1 (sr) 2018-09-28
MY192883A (en) 2022-09-13
IL268969B (en) 2020-03-31
TN2017000027A1 (en) 2018-07-04
PH12017500204A1 (en) 2017-07-10
HRP20181143T1 (hr) 2018-09-21
ZA202101003B (en) 2022-09-28
US20200383991A1 (en) 2020-12-10
CN110256427A (zh) 2019-09-20
JP6507216B2 (ja) 2019-04-24
CN106795156B (zh) 2019-07-30
ES2900599T3 (es) 2022-03-17
HUE038533T2 (hu) 2018-10-29
CR20170034A (es) 2017-04-06
CN110204544B (zh) 2022-04-12
DOP2017000038A (es) 2018-04-15
AU2015299173B2 (en) 2019-03-14
CY1120673T1 (el) 2019-12-11
UA121036C2 (uk) 2020-03-25
CN110204544A (zh) 2019-09-06
WO2016020320A1 (fr) 2016-02-11
UA123928C2 (uk) 2021-06-23
PL3395818T3 (pl) 2022-01-31
PE20170666A1 (es) 2017-06-15
PL3177619T3 (pl) 2018-09-28
US9549932B2 (en) 2017-01-24
TWI656121B (zh) 2019-04-11
IL250220B (en) 2019-09-26
MA40523A (fr) 2017-06-14
LT3177619T (lt) 2018-08-10
MX2017001637A (es) 2017-04-27
CO2017001035A2 (es) 2017-05-31
KR20200130755A (ko) 2020-11-19
HUE056676T2 (hu) 2022-02-28
TW201613920A (en) 2016-04-16
KR102180006B1 (ko) 2020-11-18
NZ728416A (en) 2021-11-26
EA035039B1 (ru) 2020-04-21
US20180256591A1 (en) 2018-09-13
ECSP17007538A (es) 2017-03-31
CU24419B1 (es) 2019-05-03
NZ765780A (en) 2023-11-24
CY1124855T1 (el) 2022-11-25
AU2019204125B2 (en) 2020-06-25
CU20170009A7 (es) 2017-07-04
EP3395818B1 (fr) 2021-09-22
IL250220A0 (en) 2017-03-30
KR20170040300A (ko) 2017-04-12
HRP20211770T1 (hr) 2022-02-18
UY36254A (es) 2016-02-29
CN110256427B (zh) 2022-02-22
JO3447B1 (ar) 2020-07-05
US9993484B2 (en) 2018-06-12
TW201922746A (zh) 2019-06-16
BR112017002221A2 (pt) 2018-05-22
EA031678B1 (ru) 2019-02-28
DK3395818T3 (en) 2021-12-13
SG11201700750UA (en) 2017-02-27
NI201700011A (es) 2017-04-20
US20160287604A1 (en) 2016-10-06
DK3177619T3 (en) 2018-08-06
EA201891861A1 (ru) 2019-01-31
CL2017000287A1 (es) 2017-11-10
BR112017002221B1 (pt) 2023-02-28
TWI700283B (zh) 2020-08-01
AP2017009702A0 (en) 2017-01-31
CA2956992A1 (fr) 2016-02-11
JP2017523987A (ja) 2017-08-24
JP2018062517A (ja) 2018-04-19
EP3177619B1 (fr) 2018-04-25
EP3177619A1 (fr) 2017-06-14
PT3177619T (pt) 2018-07-24
SA517380830B1 (ar) 2021-01-18
SI3177619T1 (en) 2018-08-31

Similar Documents

Publication Publication Date Title
MA40523B1 (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA41135B1 (fr) Benzamides substitués 1,3-thiazol-2-yl
MA35422B1 (fr) Imidazopyridazines amino-substituees
MA45020B1 (fr) Dérivés sulfonamides aromatiques
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA41562B1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MX2021004707A (es) Nuevos compuestos antihelminticos.
MA34308B1 (fr) Triazolopyridines substituées
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
EA202090448A1 (ru) Дигидрооксадиазиноны
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA38358A1 (fr) Formulations de composés organiques
MA47082B1 (fr) Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques
MA37849A1 (fr) Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux
MA43553B1 (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA38642A1 (fr) Compositions pharmaceutiques de composes triazolopyridines substitues pour une utilsation en tant qu'agents anticancereux
MA38774A1 (fr) Pyrazolo-pyridinamines substituees inhibiteurs de mknk1 kinase pour une utilisation dans les troubles hyperproliferatifs et/ou relatifs a l'angiogenese.
MA39041A1 (fr) Thiénopyrimidines en tant qu'inhibiteurs de mknk1 et de mknk2
MA38364A1 (fr) Composés imidazopyridazines substitués
MA39256A1 (fr) Benzimidazol-2-amines en tant qu'inhibiteurs midh1